<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04429893</url>
  </required_header>
  <id_info>
    <org_study_id>0304543</org_study_id>
    <nct_id>NCT04429893</nct_id>
  </id_info>
  <brief_title>Magnesium Sulphate to Bupivicaine in Serratus Anterior Plane Block in Modified Radical Mastectomy</brief_title>
  <official_title>Effectiveness of Adding Magnesium Sulphate to Bupivicaine in Ultrasound Guided Serratus Anterior Plane Block in Patients Undergoing Modified Radical Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Modified radical mastectomy may be associated with severe post-operative pain, leading to
      chronic pain syndrome which usually requires optimal perioperative pain management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly into two equal groups (forty patients each) according to the
      adjuvant added to the local anesthetic (bupivacaine) in the serratus anterior plane block
      using a computer-generated random numbers concealed in sealed opaque envelopes. Group B: The
      patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total
      volume 25 ml. Group BM: The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg
      magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of the pain intensity</measure>
    <time_frame>24 hours</time_frame>
    <description>Pain assessment by visual analogue scale</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cancer Breast</condition>
  <condition>Chronic Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Group BM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive 20 ml of 0.5% bupivacaine plus 150 mg magnesium sulphate in 0.9% normal saline with a total volume of 25 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients will receive 20 ml of 0.5% bupivacaine plus 5 ml 0.9% normal saline with total volume 25 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>magnesium sulphate</intervention_name>
    <description>assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy</description>
    <arm_group_label>Group BM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivicaine</intervention_name>
    <description>assess the pain intensity of magnesium sulphate as an adjuvant to bupivacaine in serratus anterior plane block for modified radical mastectomy</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group BM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult female patients

          -  American Society Of Anesthesiologists (ASA) class I or II

          -  scheduled for elective unilateral modified radical mastectomy

        Exclusion Criteria

          -  patient refusal

          -  bilateral breast surgery

          -  coagulation disorders

          -  body mass index&gt; 35

          -  allergy to local anaesthetics or magnesium sulphate

          -  severe respiratory or cardiac disorders

          -  pre-existing neurological deficits

          -  liver or renal insufficiency
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehab A. Abd Elaziz, Ass.Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rehab A. Abd Elaziz, Ass. Prof.</last_name>
    <phone>01001073703</phone>
    <phone_ext>020</phone_ext>
    <email>trcium2002@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rehab Abd Elraof Abd Elaziz</name>
      <address>
        <city>Alexandria</city>
        <state>Smouha</state>
        <zip>000000</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rehab A. Abd Elaziz, Ass. Prof.</last_name>
      <phone>01001073703</phone>
      <phone_ext>020</phone_ext>
      <email>trcium2002@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2020</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>rehab zayed</investigator_full_name>
    <investigator_title>Assisstant Professor of Anesthesia</investigator_title>
  </responsible_party>
  <keyword>serratus anterior plane block</keyword>
  <keyword>magnesium sulphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

